Wednesday, 25 Apr 2018

You are here

Rituximab May Halt ILD in Antisynthetase Syndrome Myositis

A multicenter study assessed patients with the antisynthetase syndrome (AS) and interstitial lung disease (ILD) and found that rituximab (RTX) therapy was associated with either improved or stable pulmonary outcomes in most. 

A retrospective analysis from the University of Pittsburgh and the Brigham and Women’s Hospital pooled their collective experience and analyzed data from 25 patients with AS-ILD, specifically assessing clinical, PFT, and chest CT outcomes using standardized scoring. 

All patients had antisynthetase antibodies (16 withJo-1, 6 PL-12, 3 PL-7). In 21/25 (84%), RTX was prescribed for recurrent or progressive ILD. CT findings included CT nonspecific interstitial pneumonia (NSIP; n = 13) and usual interstitial pneumonia (UIP)/fibrotic NSIP (n = 5), and 5 also had cryptogenic organizing pneumonia.

The 12 month outcomes, comparing pre- and post-RTX pulmonary variables, showed improvement in CT score (88%), FVC (79%), total lung capacity (from 56 ± 13 to 64 ± 13) the the glucocorticoid doses decreased from 18 ± 9 to 12 ± 12 mg/day.

DLCO (%) declined slightly at 1 year, but later increased from 42 ± 17 to 70 ± 20 at 3 years.

These uncontrolled and retrospective data provide preliminary evidence of RTX benefit when treating AS-ILD, a condition that is progressive in most patients.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

FDA Arthritis Panel Split on the Efficacy and Safety of Baricitinib in RA

On Monday, April 23rd the FDA convened the Arthritis Advisory Committee (AAC) to evaluate Lilly’s resubmitted NDA for the approval of the JAK inhibitor baricitinib for use in rheumatoid arthritis (RA). The panel included 15 voting members that included 7 rheumatologists, 3 epidemiologist-statisticians, a hematologist, 2 patient representatives and 2 pharmacologists.

IL-6 Inhibition Most Effective in Polycyclic Systemic JIA

The German Autoinflammatory Disease (AID) registry has studied the effects of the IL-6 inhibitor tocilizumab (TCZ) in systemic juvenile idiopathic arthritis (sJIA) patients and shown a clinical response rate of 35% during the first 12 weeks, and inactive disease and/or remission (with medication) in 75% at 12 months.

Anakinra May Attenuate Stroke Outcomes

The journal Stroke has published a trial wherein the use of subcutaneous IL-1Ra (anakinra) was shown to reduce the peripheral inflammatory response in those with an acute ischemic stroke. (Citation source: http://bit.ly/2uoNXEL)

FDA Panel Votes to Favor High Dose Xeljanz in Ulcerative Colitis

Yesterday a FDA advisory panel voted 15-0 in favor of approving Xeljanz (tofacitinib) 10 mg bid for patients with moderate to severe ulcerative colitis.

The US Food and Drug Administration’s (FDA) convened the Gastrointestinal Drugs Advisory Committee Meeting (GIDAC) to assess Pfizers supplemental new drug application for tofacitinib in adult patients with moderately to severely active ulcerative colitis (UC).

Abatacept Efficacy in JIA

Subcutaneous abatacept (Orencia) showed efficacy among children with polyarticular juvenile idiopathic arthritis (JIA) in an open-label phase III trial.